Cannabis Bioscience International Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cannabis Bioscience International Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $303.0K | Sep 22, 2025 |
| FY2025 | May 31, 2024 | $248.8K | Sep 22, 2025 |
| FY2024 | May 31, 2023 | $316.8K | Sep 16, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $262.9K | Sep 22, 2025 |
| FY2025 | May 31, 2024 | $203.2K | Sep 22, 2025 |
| FY2024 | May 31, 2023 | $223.4K | Sep 16, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($548.8K) | Sep 22, 2025 |
| FY2025 | May 31, 2024 | ($651.3K) | Sep 22, 2025 |
| FY2024 | May 31, 2023 | ($1.03M) | Sep 16, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($421.4K) | Sep 22, 2025 |
| FY2025 | May 31, 2024 | ($486.1K) | Sep 22, 2025 |
| FY2024 | May 31, 2023 | ($983.4K) | Sep 16, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($329.6K) | Sep 22, 2025 |
| FY2025 | May 31, 2024 | ($479.4K) | Sep 22, 2025 |
| FY2024 | May 31, 2023 | ($898.4K) | Sep 16, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $31.9K | Sep 22, 2025 |
| FY2025 | May 31, 2024 | $57.2K | Sep 22, 2025 |
| FY2024 | May 31, 2023 | $43.4K | Sep 16, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $1.20M | Sep 22, 2025 |
| FY2025 | May 31, 2024 | $1.14M | Sep 22, 2025 |
| FY2024 | May 31, 2023 | $635.0K | Sep 16, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($1.16M) | Sep 22, 2025 |
| FY2025 | May 31, 2024 | ($1.08M) | Sep 22, 2025 |
| FY2025 | May 31, 2023 | ($591.7K) | Sep 22, 2025 |
| FY2024 | May 31, 2022 | ($361.1K) | Sep 16, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($5.88M) | Sep 22, 2025 |
| FY2025 | May 31, 2024 | ($5.33M) | Sep 22, 2025 |
| FY2024 | May 31, 2023 | ($4.68M) | Sep 16, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $286.2K | Sep 22, 2025 |
| FY2025 | May 31, 2024 | $256.4K | Sep 22, 2025 |
| FY2024 | May 31, 2023 | $264.1K | Sep 16, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | 0 | Sep 22, 2025 |
| FY2025 | May 31, 2024 | 0 | Sep 22, 2025 |
| FY2024 | May 31, 2023 | 0 | Sep 16, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | 0 | Sep 22, 2025 |
| FY2025 | May 31, 2024 | 0 | Sep 22, 2025 |
| FY2024 | May 31, 2023 | 0 | Sep 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | 11.63B | Sep 22, 2025 |
| FY2025 | May 31, 2024 | 10.43B | Sep 22, 2025 |
| FY2024 | May 31, 2023 | 10.06B | Sep 16, 2024 |